Proteomics International Laboratories Ltd
ASX:PIQ

Watchlist Manager
Proteomics International Laboratories Ltd Logo
Proteomics International Laboratories Ltd
ASX:PIQ
Watchlist
Price: 0.655 AUD -2.24% Market Closed
Market Cap: 85.8m AUD
Have any thoughts about
Proteomics International Laboratories Ltd?
Write Note

Net Margin
Proteomics International Laboratories Ltd

-452.3%
Current
-336%
Average
0%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-452.3%
=
Net Income
-6.4m
/
Revenue
1.4m

Net Margin Across Competitors

Country AU
Market Cap 85.7m AUD
Net Margin
-452%
Country US
Market Cap 1.3T USD
Net Margin
9%
Country US
Market Cap 196.3B USD
Net Margin
14%
Country US
Market Cap 170.3B USD
Net Margin
18%
Country KR
Market Cap 66.5T KRW
Net Margin
24%
Country CH
Market Cap 37.6B CHF
Net Margin
9%
Country US
Market Cap 38.5B USD
Net Margin
22%
Country US
Market Cap 36.7B USD
Net Margin
9%
Country US
Market Cap 26.4B USD
Net Margin
21%
Country US
Market Cap 23B USD
Net Margin
17%
Country US
Market Cap 22.3B USD
Net Margin
-36%
No Stocks Found

Proteomics International Laboratories Ltd
Glance View

Market Cap
85.7m AUD
Industry
Life Sciences Tools & Services

Proteomics International Laboratories Ltd. is a medical technology company which operates at the forefront of predictive diagnostics and bio-analytical services. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2015-04-16. The firm is engaged in predictive diagnostics and bio-analytical services. The firm specializes in proteomics, the study of the structure and function of proteins. The firm focuses on developing and commercializing diagnostic tests for chronic diseases. The firm operates in three business units unified by a technology platform: PromarkerD, Diagnostics and Analytical Services. PromarkerD is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes. Diagnostics includes Promarker platform, used to discover, verify, and analytically validate the panel of protein biomarkers for diabetic kidney disease. Analytical Services includes proteomics-based technology platform, used to test, and validate the protein composition of a wide and varied range of products.

PIQ Intrinsic Value
0.51 AUD
Overvaluation 22%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-452.3%
=
Net Income
-6.4m
/
Revenue
1.4m
What is the Net Margin of Proteomics International Laboratories Ltd?

Based on Proteomics International Laboratories Ltd's most recent financial statements, the company has Net Margin of -452.3%.